prikaz prve stranice dokumenta Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.
The European journal of health economics, 22 (2021), 1; 1. https://doi.org/10.1007/s10198-020-01262-0
Vrdoljak, Eduard; Sekerija, Mario; Pleština, Stjepko; Belac Lovasić, Ingrid; Katalinić Janković, Vera; Garattini, Livio; Bobinac, Ana; Vončina, Luka

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Vrdoljak, E., Sekerija, M., Pleština, S., Belac Lovasić, I., Katalinić Janković, V., Garattini, L. ... Vončina, L. (2021). Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.. The European journal of health economics, 22. (1), 1. doi: 10.1007/s10198-020-01262-0

Vrdoljak, Eduard, et al. "Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.." The European journal of health economics, vol. 22, no. 1, 2021, p. 1. https://doi.org/10.1007/s10198-020-01262-0

Vrdoljak, Eduard, Mario Sekerija, Stjepko Pleština, Ingrid Belac Lovasić, Vera Katalinić Janković, Livio Garattini, Ana Bobinac and Luka Vončina. "Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.." The European journal of health economics 22, no. 1 (2021): 1. https://doi.org/10.1007/s10198-020-01262-0

Vrdoljak, E., et al. (2021) 'Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.', The European journal of health economics, 22(1), p. 1. doi: 10.1007/s10198-020-01262-0

Vrdoljak E, Sekerija M, Pleština S, Belac Lovasić I, Katalinić Janković V, Garattini L, and sur.. Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.. The European journal of health economics [Internet]. 2021 [cited 2024 November 26];22(1):1. doi: 10.1007/s10198-020-01262-0

E. Vrdoljak, et al., "Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.", The European journal of health economics, vol. 22, no. 1, p. 1, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:652428. [Accessed: 26 November 2024]

Metadata
Title (english)Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.
AuthorEduard Vrdoljak
AuthorMario Sekerija
AuthorStjepko Pleština
AuthorIngrid Belac Lovasić
AuthorVera Katalinić Janković
AuthorLivio Garattini
AuthorAna Bobinac
AuthorLuka Vončina
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Oncology and Radiotherapy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
This cost-effectiveness study analyses the expected impacts of activities proposed by the Croatian National Plan Against Cancer (NPAC) on cancer incidence and survival rates, as related to their respective costs. We evaluated the impact of the NPAC on two main outcomes, namely, reduced incidence and the improved survival of cancer patients, expressed as life years gained (LYGs), which enabled the calculation of incremental cost- effectiveness ratios (ICERs) in the form of cost per LYG. In the analysis of costs, we considered both the direct costs of NPAC activities as well as the wider indirect societal costs of cancer, thus permitting the calculation of the ICER both from the narrower national health insurer’s perspective (accounting only for the direct costs) and the wider societal perspective (accounting both for the direct and indirect costs). We estimated that on average, for all patients benefiting from the implementation of the NPAC in Croatia, an additional LYG would be yielded at the additional cost of €1.021 (societal perspective). The NPAC can, for some sites, even be considered a dominant intervention due to the negative cost/LYG ratio, meaning that it generates additional LYGs while at the same time, reducing total societal costs. Taking a narrower health insurer’s perspective (i.e., accounting only for the direct costs), the NPAC produces an additional LYG at an additional cost of €1.408. Both cost per LYG estimates can be considered cost-effective investment options.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleThe European journal of health economics
Numberingvol. 22, no. 1, p. 1
p-ISSN1618-7598
DOIhttps://doi.org/10.1007/s10198-020-01262-0
URN:NBNurn:nbn:hr:184:652428
Publication2021
Document URLhttp://bib.irb.hr/1107054
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2023-02-07 09:26:46